IFM Therapeutics

NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership Team

Retrieved on: 
Thursday, August 11, 2022

NextRNA Therapeutics , a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive Officer.

Key Points: 
  • NextRNA Therapeutics , a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive Officer.
  • Dominique is a co-founder of NextRNA who has led the scientific and corporate strategy since its launch over the past year and a half.
  • Prior to NextRNA, Dominique was formerly the Head of Academic Innovation, Center for External Innovation at Takeda Pharmaceutical Company (NYSE: TAK).
  • Dominique was previously a Principal at Third Rock Ventures, where she played an instrumental role in launching Fulcrum Therapeutics (Nasdaq: FULC) and Cedilla Therapeutics.

CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

Retrieved on: 
Thursday, June 9, 2022

CHARM Therapeutics has been created to combine these breakthroughs in 3D deep-learning with excellence in drug discovery and development, said Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics.

Key Points: 
  • CHARM Therapeutics has been created to combine these breakthroughs in 3D deep-learning with excellence in drug discovery and development, said Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics.
  • We are advancing this technology and its application to the hit discovery, hit-to-lead and lead optimization processes of small molecule drug discovery.
  • The Company is Chaired by Gary Glick, founder of IFM Therapeutics, Scorpion Therapeutics and Odyssey Therapeutics.
  • London-based CHARM Therapeutics has raised $50 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology.

CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

Retrieved on: 
Thursday, June 9, 2022

CHARM Therapeutics has been created to combine these breakthroughs in 3D deep-learning with excellence in drug discovery and development, said Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics.

Key Points: 
  • CHARM Therapeutics has been created to combine these breakthroughs in 3D deep-learning with excellence in drug discovery and development, said Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics.
  • We are advancing this technology and its application to the hit discovery, hit-to-lead and lead optimization processes of small molecule drug discovery.
  • The Company is Chaired by Gary Glick, founder of IFM Therapeutics, Scorpion Therapeutics and Odyssey Therapeutics.
  • London-based CHARM Therapeutics has raised $50 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology.

Exo Therapeutics Appoints Stephanos Ioannidis as Executive Vice President, Drug Discovery and Catherine Scholz as Senior Vice President, Program Management

Retrieved on: 
Tuesday, May 17, 2022

Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery and Catherine Scholz, PharmD, as Senior Vice President, Program Management.

Key Points: 
  • Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointments of Stephanos Ioannidis, PhD, as Executive Vice President, Drug Discovery and Catherine Scholz, PharmD, as Senior Vice President, Program Management.
  • Dr. Ioannidis has a strong record of delivering novel candidates into the clinic and experience that spans from early discovery to clinical development.
  • Prior to joining Exo, Dr. Ioannidis was Executive Vice President, Head of Discovery at IFM Therapeutics where he led the companys drug discovery group focused on innate immune system therapeutics.
  • Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets.

Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments

Retrieved on: 
Wednesday, March 9, 2022

Under his leadership, he was responsible for more than doubling the company's revenues, after which he became Chief Executive Officer of their Consumer Health Division.

Key Points: 
  • Under his leadership, he was responsible for more than doubling the company's revenues, after which he became Chief Executive Officer of their Consumer Health Division.
  • Under his leadership, Biogen completed more than 15 transactions in 2020, including partnerships with Denali Therapeutics and Sage Therapeutics, two of the largest neuroscience deals that year.
  • "We are delighted to welcome both Thomas and Will to Orna," said Tom Barnes, Ph.D., Chief Executive Officer of Orna Therapeutics.
  • Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease.

Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and Inflammation

Retrieved on: 
Wednesday, February 16, 2022

Atlas Venture founded and seeded Third Harmonic Bio in 2019 and co-led the $50 million Series A with OrbiMed with participation from BVF Partners.

Key Points: 
  • Atlas Venture founded and seeded Third Harmonic Bio in 2019 and co-led the $50 million Series A with OrbiMed with participation from BVF Partners.
  • Additional new investors in the round included Boxer Capital, RA Capital, RTW, Deep Track Capital, Ajax Health/Zeus, and Commodore Capital.
  • Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation.
  • Visit ThirdHarmonicBio.com or follow us on Twitter or LinkedIn to learn more about our work, our team, and our culture.

Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance

Retrieved on: 
Tuesday, November 16, 2021

Cedilla Therapeutics , a biotechnology company bringing a new dimension to precision oncology, today announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance.

Key Points: 
  • Cedilla Therapeutics , a biotechnology company bringing a new dimension to precision oncology, today announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance.
  • We are delighted to expand our team with these key hires, who share our passion and commitment to developing targeted medicines that conditionally modulate proteins in their functional state, said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics.
  • Dr. Murtie brings over ten years of industry experience to Cedilla.
  • He also served as Vice President of Finance at OvaScience and Senior Vice President of Finance and Administration at BIND Therapeutics.

Global STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030 - Promising Leads are Anticipated to be Launched Over the Coming Decade

Retrieved on: 
Friday, December 18, 2020

DUBLIN, Dec. 18, 2020 /PRNewswire/ -- The "STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 18, 2020 /PRNewswire/ -- The "STING Pathway Targeting Therapeutics and Technologies Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The "STING Pathway Targeting Therapeutics and Technologies" report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade.
  • In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community.
  • However, some promising leads are anticipated to be launched over the coming decade, following which the market is projected to grow at a substantial pace.

IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, January 7, 2020

BOSTON, Jan. 7, 2020 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the appointment of Michael Cooke, Ph.D., as Chief Scientific Officer.

Key Points: 
  • BOSTON, Jan. 7, 2020 /PRNewswire/ -- IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the appointment of Michael Cooke, Ph.D., as Chief Scientific Officer.
  • "At IFM Therapeutics, we have assembled a world-class team of scientists with deep experience translating scientific discovery into transformative therapies that target the innate immune system," said Dr. H. Martin Seidel, Chief Executive Officer of IFM.
  • Dr. Cooke joins IFM from Magenta Therapeutics where he most recently served as Chief Scientific Officer, leading an organization responsible for developing curative medicines for hematologic malignancy, genetic diseases and autoimmune disease through advances in bone marrow transplantation.
  • IFM Therapeutics (IFM) is an independent, privately-held biopharmaceutical company based in Boston, Massachusetts.

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

Retrieved on: 
Monday, December 2, 2019

IFM Quattro and IFM Discovery will focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.

Key Points: 
  • IFM Quattro and IFM Discovery will focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.
  • Under the terms of the financing agreement, IFM Discovery will work on a range of targets within the innate immune system.
  • In addition, IFM announced the transition of Chief Executive Officer and Co-Founder Gary D. Glick, Ph.D., into the role of Executive Chairman of the Board.
  • Effective today, IFM's Executive Vice President of Research and Development, H. Martin Seidel, Ph.D., has been named Chief Executive Officer and appointed to the Company's Board of Directors.